Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infection
W Kong, X Yang, Y Shu, S Li, B Song… - Frontiers in public …, 2023 - frontiersin.org
Background Ceftazidime-avibactam (CAZ-AVI) is a novel antibiotic that has been confirmed
in the United States and China for use in patients with carbapenem-resistant Klebsiella …
in the United States and China for use in patients with carbapenem-resistant Klebsiella …
Cost-Effectiveness of Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia and Pneumonia
ABSTRACT Ceftazidime-avibactam (CAZ-AVI) may improve outcomes among patients with
carbapenem-resistant Enterobacteriaceae (CRE) infections compared to those with …
carbapenem-resistant Enterobacteriaceae (CRE) infections compared to those with …
Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant Klebsiella pneumoniae in …
FA Varón-Vega, E Lemos, GN Castaño… - Expert Review of …, 2022 - Taylor & Francis
ABSTRACT Background Ceftazidime-Avibactam (CAZ-AVI) is a new antimicrobial against
carbapenem-resistant Klebsiella pneumoniae. The aim of the study is to examine the cost …
carbapenem-resistant Klebsiella pneumoniae. The aim of the study is to examine the cost …
[PDF][PDF] Cost-effectiveness of antimicrobial treatment for inpatients with carbapenem-resistant Klebsiella pneumoniae infection: a systematic review of economic …
Objectives: The objective of this review was to evaluate the cost-effectiveness of
antimicrobial therapy for patients with carbapenem-resistant Klebsiella pneumoniae …
antimicrobial therapy for patients with carbapenem-resistant Klebsiella pneumoniae …
Cost-effectiveness of antimicrobial treatment for inpatients with carbapenem-resistant Klebsiella pneumoniae infection: a systematic review of economic evidence
Objectives: The objective of this review was to evaluate the cost-effectiveness of
antimicrobial therapy for patients with carbapenem-resistant Klebsiella pneumoniae …
antimicrobial therapy for patients with carbapenem-resistant Klebsiella pneumoniae …
Cost-effectiveness of ceftazidime/avibactam for infections due to carbapenem-resistant bacteria in Peru
R Bolaños-Díaz, E Angles-Yanqui… - Journal of …, 2022 - academic.oup.com
Objectives The objective of this study was to analyse the cost-effectiveness (CE) of
ceftazidime/avibactam (CAZ/AVI)-based therapy versus colistin (COL)-based therapy for …
ceftazidime/avibactam (CAZ/AVI)-based therapy versus colistin (COL)-based therapy for …
Cost-Effectiveness of Short Course of Ceftazidime/Avibactam for K. pneumoniae-KPC Bloodstream Infections in Italy
I De Benedetto, N Shbaklo, C Vicentini, CM Zotti… - Microorganisms, 2023 - mdpi.com
Background: Evidence has shown that short courses of antibiotic therapy are at least as
effective as long courses with better clinical outcomes. CAZ/AVI has demonstrated its clinical …
effective as long courses with better clinical outcomes. CAZ/AVI has demonstrated its clinical …
Real-world effectiveness of ceftazidime/avibactam versus polymyxin B in treating patients with carbapenem-resistant Gram-negative bacterial infections
J Qu, J Xu, Y Liu, C Hu, C Zhong, X Lv - International Journal of …, 2023 - Elsevier
Objectives To compare the effectiveness of ceftazidime/avibactam (CAZ/AVI) and polymyxin
B against carbapenem-resistant Gram-negative bacteria (CRGNB) infections in western …
B against carbapenem-resistant Gram-negative bacteria (CRGNB) infections in western …
Cost-effectiveness analysis of vaborem for the treatment of carbapenem-resistant Enterobacteriaceae-Klebsiella pneumoniae carbapenemase (CRE-KPC) infections …
I Vlachaki, D Zinzi, E Falla, T Mantopoulos… - The European Journal of …, 2022 - Springer
Objective The study objective of this analysis was to determine the cost-effectiveness of
vaborem (meropenem-vaborbactam) compared to the best available therapy (BAT) in adult …
vaborem (meropenem-vaborbactam) compared to the best available therapy (BAT) in adult …
Prevalence and mortality of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae bloodstream infections (2018–2022)
M Boattini, G Bianco, P Bastos, S Comini… - European Journal of …, 2024 - Springer
Introduction Ceftazidime/avibactam-resistance in Klebsiella pneumoniae carbapenemase-
producing Klebsiella pneumoniae (KPC-Kp) is a topic of great interest for epidemiological …
producing Klebsiella pneumoniae (KPC-Kp) is a topic of great interest for epidemiological …